Dr. Rui Meng 孟睿
Chief Physician, Associate Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, radiotherapy, and targeted therapy for thoracic tumors.
Dr. Meng is Chief Physician, Associate Professor, and Master’s Supervisor. Dr. Meng leads Ward IV of Thoracic Tumors at the Cancer Center, Union Hospital. Training includes a Ph.D. from Germany (state-sponsored) and a doctorate in oncology from Huazhong University of Science and Technology. Dr. Meng was selected for Wuhan’s Medical Backbone Talent Program.
Professional roles
- Vice Chair, Youth Committee of the Lung Tumor Professional Committee, China Medicine Education Association
- Member, Lung Cancer Professional Committee, China South Oncology Clinical Research Association (CSWOG)
- Standing Committee Member, Tumor Molecular Targeted Therapy Professional Committee, Hubei Anti-Cancer Association
- Member, Expert Committee on Tumor Nutritional Therapy, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Meng Rui). Papers usually list the name as Rui Meng or Meng R.
Selected publications
88 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Mol Sci, 2026 (senior author): Integrating Single-Cell, Bulk, and Spatial Transcriptomics Unveils a Novel Ribosome Biogenesis-Related Prognostic Model and Defines RPS19BP1 as a Pro-Oncogenic Regulator in Lung Adenocarcinoma. PubMed 42450135
- Exp Hematol Oncol, 2026 (senior author): Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade. PubMed 42106865
- Discov Oncol, 2026 (senior author): Durable response to immunotherapy in NSCLC with duodenal metastasis. PubMed 41557106
- Clin Respir J, 2024 (senior author): Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome. PubMed 39681089
- Indian J Pathol Microbiol, 2024 (senior author): Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report. PubMed 38358227
- Transl Lung Cancer Res, 2023 (senior author): Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases. PubMed 38090524
- Discov Oncol, 2023 (senior author): The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics. PubMed 37326784
- Open Life Sci, 2023 (senior author): An unusual ectopic thymoma clonal evolution analysis: A case report. PubMed 37215501
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion